MX381305B - Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis. - Google Patents

Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis.

Info

Publication number
MX381305B
MX381305B MX2017006244A MX2017006244A MX381305B MX 381305 B MX381305 B MX 381305B MX 2017006244 A MX2017006244 A MX 2017006244A MX 2017006244 A MX2017006244 A MX 2017006244A MX 381305 B MX381305 B MX 381305B
Authority
MX
Mexico
Prior art keywords
sub
atp
syndrome
methods
prader
Prior art date
Application number
MX2017006244A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006244A (es
Inventor
Neil M Cowen
Original Assignee
Essentialis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essentialis Inc filed Critical Essentialis Inc
Publication of MX2017006244A publication Critical patent/MX2017006244A/es
Publication of MX381305B publication Critical patent/MX381305B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017006244A 2014-11-14 2015-11-12 Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis. MX381305B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462080150P 2014-11-14 2014-11-14
US201562138245P 2015-03-25 2015-03-25
US201562170035P 2015-06-02 2015-06-02
US201562221359P 2015-09-21 2015-09-21
PCT/US2015/060455 WO2016077629A1 (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Publications (2)

Publication Number Publication Date
MX2017006244A MX2017006244A (es) 2018-02-26
MX381305B true MX381305B (es) 2025-03-12

Family

ID=55955075

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006244A MX381305B (es) 2014-11-14 2015-11-12 Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis.
MX2021003982A MX393030B (es) 2014-11-14 2015-11-12 Activador del canal de katp para usarse en el incremento de la masa muscular del miembro inferior en un sujeto que padece el síndrome de smith-magenis (sms)

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003982A MX393030B (es) 2014-11-14 2015-11-12 Activador del canal de katp para usarse en el incremento de la masa muscular del miembro inferior en un sujeto que padece el síndrome de smith-magenis (sms)

Country Status (19)

Country Link
US (8) US10058557B2 (OSRAM)
EP (1) EP3217963B1 (OSRAM)
JP (4) JP6709226B2 (OSRAM)
KR (4) KR102598666B1 (OSRAM)
CN (2) CN107106500B (OSRAM)
AU (2) AU2015346196B2 (OSRAM)
BR (1) BR112017009986A2 (OSRAM)
CA (4) CA3125839C (OSRAM)
DK (1) DK3217963T3 (OSRAM)
EA (1) EA036103B1 (OSRAM)
ES (1) ES2806977T3 (OSRAM)
HU (1) HUE050895T2 (OSRAM)
IL (1) IL252111B (OSRAM)
MX (2) MX381305B (OSRAM)
MY (1) MY187610A (OSRAM)
NZ (1) NZ768958A (OSRAM)
PL (1) PL3217963T3 (OSRAM)
SG (1) SG11201703721SA (OSRAM)
WO (1) WO2016077629A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060051418A1 (en) 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
JP5543110B2 (ja) 2006-01-05 2014-07-09 エッセンシャリス，インク． カリウムａｔｐチャネルオープナの塩およびその使用
CN107106500B (zh) 2014-11-14 2021-07-30 伊森舍丽斯有限公司 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法
RU2021114228A (ru) 2016-06-03 2021-06-01 Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк Способ лечения синдрома прадера-вилли
AU2018261756B2 (en) 2017-05-05 2022-01-20 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
EP3852723B1 (en) * 2018-09-20 2025-11-05 ACADIA Pharmaceuticals Inc. Stable intranasal formulations of carbetocin
CN111888330B (zh) * 2020-09-18 2022-08-16 常州市第四制药厂有限公司 一种二氮嗪口服混悬溶液及制备方法
AU2023365206A1 (en) * 2022-10-18 2025-04-24 Rhythm Pharmaceuticals, Inc. Novel atp-sensitive potassium channel potentiators, their preparation and use
WO2025057119A1 (en) * 2023-09-15 2025-03-20 Soleno Therapeutics, Inc. Methods of managing glycemic control in prader-willi syndrome patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2986573A (en) 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5284845A (en) 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5629045A (en) 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO1998010786A2 (en) 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
US6197765B1 (en) 1999-06-08 2001-03-06 Pnina Vardi Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
WO2002000222A1 (en) 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for the treatment of cancer
TW478039B (en) 2001-04-09 2002-03-01 Promos Technologies Inc Phase shift alignment system
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
AU2003287640A1 (en) 2002-11-12 2004-06-03 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
JP2008503548A (ja) 2004-06-23 2008-02-07 ニューロテック、ファルマ、ソシエダッド、リミターダ 中枢神経系の炎症の治療のための化合物
US20060051418A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
CN101043879A (zh) * 2004-08-25 2007-09-26 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
AU2005298692A1 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
JP5543110B2 (ja) 2006-01-05 2014-07-09 エッセンシャリス，インク． カリウムａｔｐチャネルオープナの塩およびその使用
CA2655144A1 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
US20120238554A1 (en) 2007-07-02 2012-09-20 Cowen Neil M Salts of potassium atp channel openers and uses thereof
US20090062264A1 (en) * 2007-07-02 2009-03-05 Cowen Neil M Salts of potassium atp channel openers and uses thereof
US20120053172A1 (en) * 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20140336109A1 (en) * 2011-12-15 2014-11-13 Alize Pharma Sas Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
JP2014074004A (ja) * 2012-10-05 2014-04-24 Shinichi Niijima 精神症状の改善剤
US20140364367A1 (en) 2013-06-08 2014-12-11 Sedogen, Llc Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
CN107106500B (zh) 2014-11-14 2021-07-30 伊森舍丽斯有限公司 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法

Also Published As

Publication number Publication date
CA3125835C (en) 2023-01-03
KR20220124289A (ko) 2022-09-13
EA036103B1 (ru) 2020-09-29
CA3210794A1 (en) 2016-05-19
KR102323613B1 (ko) 2021-11-09
JP6709226B2 (ja) 2020-06-10
EA201791067A1 (ru) 2017-11-30
AU2015346196A1 (en) 2017-06-29
CA3125839A1 (en) 2016-05-19
NZ768958A (en) 2021-07-30
IL252111B (en) 2021-09-30
US20190105327A1 (en) 2019-04-11
JP2021193148A (ja) 2021-12-23
MX2021003982A (es) 2022-06-09
JP7232300B2 (ja) 2023-03-02
US12419895B1 (en) 2025-09-23
KR20210134843A (ko) 2021-11-10
US10874676B2 (en) 2020-12-29
MX393030B (es) 2025-03-24
CA3125835A1 (en) 2016-05-19
KR20230049760A (ko) 2023-04-13
NZ731565A (en) 2021-06-25
US20180021344A1 (en) 2018-01-25
US20210322434A1 (en) 2021-10-21
WO2016077629A1 (en) 2016-05-19
KR102452254B1 (ko) 2022-10-11
MX2017006244A (es) 2018-02-26
CA2966907C (en) 2021-09-07
US12109216B2 (en) 2024-10-08
SG11201703721SA (en) 2017-06-29
JP7645913B2 (ja) 2025-03-14
AU2015346196B2 (en) 2019-01-31
ES2806977T3 (es) 2021-02-19
CN113599386B (zh) 2025-12-05
US10456408B2 (en) 2019-10-29
BR112017009986A2 (pt) 2018-02-14
KR102517840B1 (ko) 2023-04-05
US10058557B2 (en) 2018-08-28
US20250288593A1 (en) 2025-09-18
JP6955039B2 (ja) 2021-10-27
CA2966907A1 (en) 2016-05-19
HUE050895T2 (hu) 2021-01-28
KR102598666B1 (ko) 2023-11-07
DK3217963T3 (da) 2020-07-20
IL252111A0 (en) 2017-07-31
KR20170082625A (ko) 2017-07-14
EP3217963A4 (en) 2018-07-04
US20240423996A1 (en) 2024-12-26
US12343348B2 (en) 2025-07-01
PL3217963T3 (pl) 2020-10-19
CA3125839C (en) 2023-10-24
CN113599386A (zh) 2021-11-05
US12178823B1 (en) 2024-12-31
EP3217963B1 (en) 2020-05-20
AU2019202906B2 (en) 2020-05-21
US20200147100A1 (en) 2020-05-14
AU2019202906A1 (en) 2019-05-16
JP2023056025A (ja) 2023-04-18
CN107106500A (zh) 2017-08-29
EP3217963A1 (en) 2017-09-20
US20240207284A1 (en) 2024-06-27
MY187610A (en) 2021-10-04
JP2017533972A (ja) 2017-11-16
CN107106500B (zh) 2021-07-30
JP2020073566A (ja) 2020-05-14
HK1243954A1 (en) 2018-07-27
US20250120979A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
MX381305B (es) Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis.
DK1968601T3 (da) Salte af kalium-ATP-kanalåbnere og anvendelser heraf
DK1781265T3 (da) Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MY188139A (en) Sodium channel modulators for the treatment of pain
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
AR086051A1 (es) Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
MX386251B (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
MX376200B (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia.
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MA39743A (fr) Fumarate de diméthyle et régimes de vaccination
EA201591902A1 (ru) Способы и композиции, использующие 4-амино-2-(2,6-диоксо-пиперидин-3-ил)изоиндолин-1,3-дион для лечения и контроля злокачественных опухолей центральной нервной системы
MY205748A (en) Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
TW201642854A (en) Fixed dose combination for pain relief without edema
MX391734B (es) COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE IgG PARA EL TRATAMIENTO DE UNA INMUNODEFICIENCIA.
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
HK1142824A (en) Salts of potassium atp channel openers and uses thereof
Cosme Amoxicillin/clarithromycin/metronidazole/omeprazole